SecBot SecBot
SECBOTREPLAY Home › Report › LFWD

LFWD · Lifeward Ltd

Lifeward Ltd. · PRESS-RELEASE filed Mar 25, 2026 at 16:10 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 25, 2026 at 16:10 ET

Lifeward Ltd. has closed a strategic partnership with Oramed Pharmaceuticals, acquiring Oramed's clinical-stage Protein Oral Delivery (POD™) technology and securing access to up to $47 million in capital, of which $10 million was drawn on March 25, 2026. The deal transforms Lifeward into a diversified biomedical innovation company with expanded exposure to the biotech market.

  • Lifeward acquired Oramed Pharmaceuticals' clinical-stage POD™ technology.
  • The partnership provides Lifeward access to up to $47 million in capital.
  • $10 million of capital was accessed on March 25, 2026.
  • Lifeward has repositioned as a diversified biomedical innovation company.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access